Ser39

Site Information
KRRAREVsDLQEEGK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23129404
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	gastric cancer ( 2 ) , gastric carcinoma ( 2 ) , lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 ) , non-small cell squamous cell lung carcinoma ( 1 )
Relevant cell line - cell type - tissue:	A498 (renal) ( 3 ) , HCC15 (pulmonary) ( 1 ) , LOU-NH91 (squamous) ( 1 ) , lung ( 1 ) , MKN-45 (gastric) ( 2 ) , NCI-H1703 (squamous) ( 1 ) , NCI-H2073 (pulmonary) ( 1 ) , NCI-H2342 (pulmonary) ( 1 )

References
1	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
2	Moritz A (2011) CST Curation Set: 11938; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
3	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info